脑脊液髓鞘碱性蛋白抗体检测对格林-巴利综合征的临床价值

The Clinical Evaluation of Determining Antibody to Myelin Basic Protein in Cerebrospinal Fluid of Patients with Guillain-Barre Syndrome

目的探讨格林-巴利综合征（GBS）中枢神经髓鞘的免疫性损伤。方法GBS患者20例，神经系统其它疾病组（OND）20例，非神经系统疾病手术者33例。以酶联免疫吸附法检测73份脑脊液（CSF）中髓鞘碱性蛋白IgG（MBP－IgG）。结果GBS患者、OND患者和非神经系统疾病手术者CSF中MBP－IgG阳性率分别为55％、30％和9.1％。GBS患者CSF中MBP-IgG阳性率与发病天数有关。结论部分GBS有中枢神经髓鞘的免疫性损害，证实GBS是自身免疫性脱髓鞘病。

To investigate the immune injury of myelin from central nervous system in patients with Guillain-Barre syndrome (GBS). Methods The myelin basic protein (MBP)antibody was assayed in cerebrospinal fluid (CSF) from 20 cases of GBS, 20 case others neural diseases (OND) and 33 cases operated patients without nervous system diseases by enzyme linked immunosorbent assay (ELISA). Results The possitive rates of MBP-IgG was found 55 % in GBS, 30% in OND and 9.1 % in operated patients without nervous system diseases. and was relevant to the onset days of GBS. Conclusions GBS was considered to be an autoimmune demyelinating disease.